Vitamin D, reducing fat oxidation may treat lung fibrosis, COVID-19

haidut

Member
Forum Supporter
Joined
Mar 18, 2013
Messages
19,798
Location
USA / Europe
Pulmonary fibrosis, regardless of etiology, is considered invariably a progressive and fatal disease. Despite this official story, behind the scenes several pharma companies are running clinical trials with several anti-fibrotic agents and the results so-far demonstrate that the condition is both preventable and treatable. The most advanced trial so far is the one run by Pfizer with the serotonin antagonist terguride (dihydro-lisuride), which is expected to result in approval of that drug some time in 2022. The drug seems to be effective not just for lung fibrosis, but also for heart, kidney, liver and even pancreatic fibrosis. So, there good evidence that serotonin is a major cause of fibrotic diseases. Now, the study below demonstrates that lung fibrosis is yet another condition that can be triggered by metabolic dysfunction implicated in "traditional" metabolic diseases such as diabetes. Namely, the study found that increased fatty acid oxidation (FAO) is responsible for blocking apoptosis, increasing inflammation and thus enabling fibrosis. As such, blocking fatty acid oxidation seems like a viable pathway for both preventing and treating fibrotic conditions. Interestingly enough, the second study below demonstrates that vitamin D may also serve as prevention/treatment, though the mechanism described in the study is inhibition of the renin-angiotensin-aldosterone system (RAAS), which is apparently overactive in fibrotic conditions and corroborated by the fact that aldosterone antagonists such as spironolactone are common treatments for heart fibrosis. As such, the second study also suggests that other aldosterone antagonists such as pregnenolone and progesterone should also demonstrate therapeutic effects for fibrotic conditions in many organs/tissues, including the lungs. The second study also corroborates other recent posts on this blog discussing vitamin D ability to block/treat fibrotic changes in organs such as the liver, and suggests that vitamin D has a generic anti-fibrotic effect. One other possible mechanism for the therapeutic effects of vitamin D may be through its ability to inhibit the enzyme TPH (which synthesizes serotonin), making it similar in effects to anti-serotonin agents such as terguride/lisuride. Be that as it may, the studies below demonstrate both that yet another lethal, "incurable" disease is anything but, while also demonstrating that cheap and widely available OTC supplements such as vitamin D, pregnenolone/progesterone, and niacinamide/aspirin (which reduce FAO and lipolysis) may be its viable treatments, and accessible to all. And last but not least, the second study demonstrates that the effects of vitamin D on the RAAS system are virtually identical to the drug losartan. This corroborates the findings that vitamin D levels are crucial determinant of COVID-19 vulnerability, as well as the hypothesis that (similar to losartan) vitamin D may be a viable prevention/treatment for COVID-19.

Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling - Cell Death & Differentiation
"...The deletion of Bcl-2 in macrophages protected mice from developing pulmonary fibrosis. Moreover, mice had resolution when Bcl-2 was deleted or was inhibited with ABT-199 after fibrosis was established. These observations implicate an interplay between macrophage fatty acid β-oxidation, apoptosis resistance, and dysregulated fibrotic remodeling."

Lung fibrosis in mice successfully reversed by scientists
"...In this study, mice were given bleomycin for 12 days to establish lung fibrosis and treated daily until 21 days with ABT-199, also known as Venetoclax, an approved leukaemia medication. The researchers found increased mitochondrial B-cell lymphoma-2 (Bcl-2) in the mitochondria of lung macrophages from bleomycin mice, as well as an increase in two proteins: mitochondrial calcium uniporter (MCU) and carnitine palmitoyltransferase 1a (Cpt1a), an enzyme in mitochondria that is the rate-limiting step for the fatty acid beta-oxidation energy pathway. MCU was previously known to regulate metabolic reprogramming of lung macrophages to fatty acid oxidation and acts in the progression of lung fibrosis and apoptosis resistance."

"...Taken together, these observations suggest that fatty acid oxidation provokes apoptosis resistance through the stabilisation of Bcl-2 in the mitochondria by binding to Cpt1a,” said Professor Brent Carter, who led the study. “Moreover, these data demonstrate that monocyte-derived macrophages are required for fibrosis progression and they suggest a novel therapeutic target to prevent progressive aberrant fibrotic remodelling.”"

Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin–angiotensin system in the lung - Scientific Reports
"...IPF, a form of pulmonary fibrosis with no clear cause, is characterized by excessive wound healing that leads to fibrosis and increased stiffness of lung tissue, making it difficult for patients to breathe. A growing number of studies have described several non-classic functions of the vitamin D hormone, besides its well-known role in regulating calcium balance and bone health. The sunshine vitamin, as it is often called, is known to also have antioxidant, anti-inflammatory, and anti-fibrotic effects. Previous research associated vitamin D deficiency with a higher risk of death among IPF patients, and showed that oral vitamin D supplementation can reduce lung fibrosis in a mouse model. However, the mechanisms by which vitamin D exerts its anti-fibrotic effects remain largely unknown. A team of researchers in the U.S. and China found strong evidence indicating that vitamin D’s anti-fibrotic action involves RAS, a signaling pathway mainly known for its role in regulating blood pressure, fluid and salt balance in the body. RAS is also involved in fibrosis. Notably, angiotensin II (Ang II), the main effector molecule of RAS signaling, “is well known to have potent pro-inflammatory and pro-fibrotic activities, which are mediated by angiotensin receptor type 1 (AT1R),” the researchers wrote. The team had previously shown that mice genetically modified to have chronic RAS activation spontaneously developed progressive lung fibrosis. In the current study, the researchers used a mouse model of induced IPF to assess the effects of vitamin D on lung fibrosis. They found that treatment with paricalcitol, an active form of vitamin D with low calcium-related activity, prevented disease-associated weight loss and significantly lessened lung fibrosis and the levels of fibrotic markers — in some cases, reaching levels seen in healthy mice. Vitamin D’s protective role was also supported by mice that, after being fed a low-vitamin D diet and developing vitamin D deficiency, had more severe weight loss and lung scarring than those ingesting a sufficient amount of the vitamin. The vitamin D-deficient diet by itself was also found to promote lung fibrosis in healthy mice. Further analyses revealed a significant increase in the levels of RAS-related molecules, such as renin, Ang II, and AT1R, in the lungs of the IPF mouse model relative to healthy mice, suggesting a strong fibrosis-associated RAS activation. Notably, this activation was significantly blocked in paricalcitol-treated mice. Treatment with losartan — a medication for high blood pressure that blocks AT1R — also reduced weight loss, substantially lessened lung fibrosis, and significantly blocked TGF-beta 1 induction in the lungs of vitamin D-deficient, IPF-induced mice. TGF-beta 1 is a known driver of pulmonary fibrosis. The active form of vitamin D hormone was also found to markedly suppress the pro-fibrotic effects of TGF-beta 1 and Ang II in lab-grown mouse lung cells. These findings “strongly suggest that vitamin D mitigates lung fibrosis by blocking the activation of the lung RAS in this mouse model of IPF,” the researchers wrote. “The therapeutic implication of this conclusion is that low calcemic vitamin D analogs [similar molecules] and anti-RAS [therapies] may be useful for the management of human IPF,” the team wrote."

 
Last edited:

Mauritio

Member
Joined
Feb 26, 2018
Messages
5,669
Great post .
What was the dosage of vitamin D?
 
OP
haidut

haidut

Member
Forum Supporter
Joined
Mar 18, 2013
Messages
19,798
Location
USA / Europe
Great post .
What was the dosage of vitamin D?

They used a synthetic vitamin D analog they claim did not have hypercalcemic effects. However, they also had a group of mice on regular diet replete with vitamin D at normal levels and those mice did not develop fibrosis. So, for prevention the usual 2,000-3,000 IU daily probably suffice and for treatment, I'd take a dose that raises the blood levels to about 80. Levels around 50 have been shown to be best for long-term health.
 

Mauritio

Member
Joined
Feb 26, 2018
Messages
5,669
They used a synthetic vitamin D analog they claim did not have hypercalcemic effects. However, they also had a group of mice on regular diet replete with vitamin D at normal levels and those mice did not develop fibrosis. So, for prevention the usual 2,000-3,000 IU daily probably suffice and for treatment, I'd take a dose that raises the blood levels to about 80. Levels around 50 have been shown to be best for long-term health.
Great ,thanks!
 

fr@

Member
Joined
Jun 18, 2021
Messages
279
Location
Gabriola
@haidut

Is it okay to just take D3 without any dietary or supplemental Vitamin-K?
Though there's a lot that says it would be 'safer' to take the supplement form of D3 with K2, but what's your personal take on it?

'Cause lately I've tried MK-4 again under the tough (just 1 drop) and it immediately got me fatigued for the entire day.
Normally, I'm using MK-4 topically.
So now, I've stopped taking all Vitamin-K supplements just to recover from it.
 
P

Peatness

Guest
 

aliml

Member
Joined
Apr 17, 2017
Messages
692
Patients on the Marshall Protocol (MP) take olmesartan (Benicar), a drug whose actions are well known, every six hours. In general, olmesartan tends to be prescribed for its antihypertensive properties due to the fact that is an angiotensin receptor blocker. A growing body of research supports the use of olmesartan as a part of a curative therapy for chronic disease.

For the purposes of the MP, olmesartan has two primary actions: it reduces inflammation by blocking the Nuclear Factor-kappaB cytokine pathway and it is an agonist of the Vitamin D Receptor (VDR). As a VDR agonist, olmesartan uniquely activates the innate immune response. Research supports the safety of the doses used by MP patients.

Vitamin D receptor (VDR) agonists are well known for their capacity to control calcium metabolism and to regulate growth and differentiation of many cell types. More recently, it has become clear that VDR agonists possess immunoregulatory properties and, in particular, pronounced pro-tolerogenic activities…. These mechanisms of action can explain some of the immunoregulatory properties of VDR agonists in the treatment of Th1-mediated autoimmune diseases, but may also represent a physiologic element in the VDR-mediated regulation of innate and adaptive immune responses.

 

Mauritio

Member
Joined
Feb 26, 2018
Messages
5,669
... "a mortality rate close to zero could theoretically be achieved at 50 ng/ml 25(OH)D3..."

It's too risky though, would be unethical to make placebo studies ,with dangerous vitamin D ?
 

Jam

Member
Joined
Aug 10, 2018
Messages
2,212
Age
52
Location
Piedmont
@haidut

Is it okay to just take D3 without any dietary or supplemental Vitamin-K?
Though there's a lot that says it would be 'safer' to take the supplement form of D3 with K2, but what's your personal take on it?

'Cause lately I've tried MK-4 again under the tough (just 1 drop) and it immediately got me fatigued for the entire day.
Normally, I'm using MK-4 topically.
So now, I've stopped taking all Vitamin-K supplements just to recover from it.
In my experience, negative reactions to K2 can indicate a need for supplemental D3.
 

fr@

Member
Joined
Jun 18, 2021
Messages
279
Location
Gabriola
In my experience, negative reactions to K2 can indicate a need for supplemental D3.
Thanks, I'll keep that in mind -- I guess the D3 I'm taking is too low to accommodate K2 supplementation.
 

aliml

Member
Joined
Apr 17, 2017
Messages
692
CPT1A (carnitine palmitoyltransferase 1A) is the key enzyme in transporting components of fatty acids onto carnitine across the mitochondrial inner membrane. This is an essential step to having these fatty acids burned as energy.

Substances That Decrease CPT1A:

-- Oxygen
-- Ozone
-- Glucose
-- Vitamin E
-- Betaine HCl
-- Tetracycline
-- Losartan
-- Berberine
-- Metformin
-- Methapyrilene
-- THC
-- Galactosamine
-- Hydralazine
-- Sodium Selenite
-- Methionine
-- Choline
-- Tamoxifen
-- Wortmannin
-- Streptozocin
-- Streptozocin
-- Vanadyl Sulfate
-- Copper Sulfate
-- Dexrazoxane
-- Cyclosporine
-- Glabridin / Licorice CO2 Extract
-- ALA / Alpha-Lipoic Acid
-- CLA / Conjugated Linoleic Acid
-- Rotenone / Jicama & Yam
-- Tetrahydropalmatine / Corydalis Plants
-- Palmitoyl-CoA / Palmitic Acid Activated Form
-- Valproyl-CoA / Valproate Active Metabolite
-- Phlorhizin / Apple Leaves
-- Tectoridin / Pueraria Plants
-- Zerumbone / Wild Ginger
-- Dioscin / Fenugreek & Yam
-- Ciklavit / Pigeon Pea Aqueous Extract

 

Perry Staltic

Member
Joined
Dec 14, 2020
Messages
8,186
And stop taking SSRI/SNRI harmaceuticals. They are agonists of 5HT2b which promotes fibrosis. An ounce of prevention is worth a pound of cure.


 

Perry Staltic

Member
Joined
Dec 14, 2020
Messages
8,186
And stop taking SSRI/SNRI harmaceuticals. They are agonists of 5HT2b which promotes fibrosis. An ounce of prevention is worth a pound of cure.



This case from the 2nd study really gets me. The patient's SNRI dosage was doubled and within one day she noticeably deteriorated with breathlessness and low blood sat. It makes me wonder how many depressed people during the lockdowns had their antidepressant doses upped (via telemed), suffered similar reactions, went to the ER from fear of covid and had chest xrays (CXR) that showed lung fibrosis. Remember, lung fibrosis is a reported effect of covid. That low of blood sat would have had them on ventilators with predictable results.

On December 22, 2014, she was found to be depressed. She had been on venlafaxine 37.5 mg OD since May 2004. Venlafaxine was increased to 75 mg OD. On December 23, 2014, there was a severe deterioration in her mobility, fatigue, and breathlessness. There was no cough, fever, or symptoms of acute infection. O2 saturation was 87% on 2 L/m, dropping to 80% with walking. There were bilateral coarse crackles throughout her lungs. Other clinical findings included: JVP 3 cm, HR 68, BP 102/68 mmHg, and +1 edema. CXR was reported as cardiomegaly with diffuse pulmonary fibrosis. BNP was 1,741 ng/L. She refused to undergo CT. Diuresis with furosemide did not improve her symptoms nor oxygen saturations. Her medications were reviewed and venlafaxine was discontinued because of previous case reports linking it to ILD. After discontinuing venlafaxine, there was a significant improvement in her dyspnea, fatigue, mobility, and oxygen saturation. The crackles from her lungs had largely cleared except for her bases. By February 19, 2015, she was back to baseline function.
 
Last edited:

Birdie

Member
Joined
Aug 10, 2012
Messages
5,783
Location
USA
This case from the 2nd study really gets me. The patient's SNRI dosage was doubled and within one day she noticeably deteriorated with breathlessness and low blood sat. It makes me wonder how many depressed people during the lockdowns had their antidepressant doses upped (via telemed), suffered similar reactions, went to the ER from fear of covid and had chest xrays (CXR) that showed lung fibrosis. Remember, lung fibrosis is a reported effect of covid. That low of blood sat would have had them on ventilators with predictable results.
I'd read that the SNRIs were making people more susceptible to Covid, but this is an intriguing twist.
 

Perry Staltic

Member
Joined
Dec 14, 2020
Messages
8,186
I'd read that the SNRIs were making people more susceptible to Covid, but this is an intriguing twist.

One study found that mental disorders were the 2nd highest risk factor after obesity. Really makes me wonder...
 

Birdie

Member
Joined
Aug 10, 2012
Messages
5,783
Location
USA
And stop taking SSRI/SNRI harmaceuticals. They are agonists of 5HT2b which promotes fibrosis. An ounce of prevention is worth a pound of cure.


Like the term - harmaceuticals. You know, a neighbor asked me last year what I did to treat the flu last time I had it. (I'd told him it was 40 years ago). I was hard put to remember, but figured I took some vitamin C.

He uses every drug the doctor advises and has lots of health problems. He couldn't understand why I'd never had a flu shot. That's what started the conversation.
He probably uses SSRIs because he thinks all medical advice is good.

I see your comment about the mental disorder risk factor. Yes, prob the meds (pharmaceuticals) for the mental disorders are the risk factor.
 

Birdie

Member
Joined
Aug 10, 2012
Messages
5,783
Location
USA
I've read the first few sentences in the block you posted @haidut . Looks good. I have to copy and paste it, and divide it into smaller paragraphs so I can actually read it though! If you could add paragraphs when you make these interesting posts, it would make for easier reading... at least for me. ;)
 

Lollipop2

Member
Joined
Nov 18, 2019
Messages
5,267
This case from the 2nd study really gets me. The patient's SNRI dosage was doubled and within one day she noticeably deteriorated with breathlessness and low blood sat. It makes me wonder how many depressed people during the lockdowns had their antidepressant doses upped (via telemed), suffered similar reactions, went to the ER from fear of covid and had chest xrays (CXR) that showed lung fibrosis. Remember, lung fibrosis is a reported effect of covid. That low of blood sat would have had them on ventilators with predictable results.
Interesting thought. Highly plausible.
 

Similar threads

Back
Top Bottom